PrEP: A Case-by-Case Approach

Slides:

Advertisements

Similar presentations

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.

Advertisements

PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

HIV Prevention Biomedical A New Landmark in the Field of HIV Treatment

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.

HIV Modelling & Economics Estimating the potential impact and efficiency of PrEP for FSWs and MSM in Bangalore, southern India K.M. Mitchell 1, H.J. Prudden.

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study MC Thigpen,

Use of Antivirals in Prevention Oral and Topical Prophylaxis

The potential and challenges of ARV-based HIV prevention: An overview

Safer Conception for Sero-Discordant Couples Judy Levison, MD, MPH Associate Professor, Departments of Obstetrics and Gynecology and Family and Community.

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

A PEP and PrEP Update Jeffrey D. Klausner, MD, MPH Black AIDS Institute-UCLA African-American University September 2014 Special thanks to Raphael Landovitz,

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

PRECONCEPTION COUNSELING AND CARE FOR HIV-INFECTED WOMEN OF CHILDBEARING AGE.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

Washington D.C., USA, July 2012www.aids2012.org Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic.

New Prevention Technologies Workshop Module 2: NPTs in context

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

The tipping point: When do placebos become unethical? Bridget Haire.

PrEP Facts Clinical trials have shown daily oral Tenofovir to effectively prevent HIV acquisition PrEP must only be prescribed for HIV- patients and patients.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Session: Treatment is Prevention? 16 th International Conference on AIDS and Sexually Transmitted Infections in Africa, Addis Ababa, Ethiopia Catherine.

Upfront Combination Therapy vs Step-Up Approach for PAH:

What’s New in the Perinatal Guidelines

HIV and the ART of Prevention

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Managing Women Living With HIV Infection

Program Goals Overview of HIV Epidemic HIV and Communities of Color.

The Possibilities of PrEP: Introduction

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

PAD Patients vs Post-ACS Patients:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

PrEP in Women: Unique Considerations and Strategies

Translating Emerging HIV Data Into Clinical Practice

Tailoring Hemophilia Prophylaxis Therapy

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Is it Time for a Paradigm Change in HIV Management?

Initiating Pre-exposure Prophylaxis The PrEP Checklist

A Better Solution For Cancer Patients With VTE?

HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

PrEP Ongoing Care.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

When to Start and What to Use

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Patient Questions and Expert Answers in Psoriasis:

Insulin in Diabetes Management: Effective Patient Selection Is Key

Proteasome Inhibitors and Patients

Analytic framework illustrating exposure to preventive measures that reduce the risk of transmission between HIV-serodiscordant sex partners. Analytic.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Undetectable = Untransmittable

Bob Holtkamp, Director of Prevention & Outreach

Presentation transcript:

PrEP: A Case-by-Case Approach

Program Goals

Case 1: Serodiscordant Male Couple

Options to Consider

Promoting Condom Use

HPTN 052: Study Design

HPTN 052: HIV Transmission Events

HPTN 052: HIV Transmission Events (cont)

HIV Preexposure Prophylaxis

Risk Reduction by Drug Concentration in iPrEx

CDC Interim Guidance on PrEP Use

PrEP, Antiretroviral Therapy, or Both for Serodiscordant Couples?

Antiretroviral Therapy vs PrEP vs Both: Key Decision Points

Case 2: A Popular Young Man

Efficacy of Oral Tenofovir/Emtricitabine PrEP in Patient Subgroups

iPrEx: Predictors of Adherence

PrEP Use and Social Harms

HIV Infections During PrEP Trials in the United States

Case 3: Flu-like Illness

Acute HIV Infection

Case 4: PrEP in Women?

Efficacy of Daily Oral Emtricitabine/Tenofovir PrEP in Women

Adherence is the Key Factor for PrEP Efficacy

PrEP Can Facilitate Antiretroviral Therapy for the Infected Partner

Concluding Remarks

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)